In correlation, clinical data from patients with melanoma, HNSCC, and gastric cancer revealed that gene expression profiles (GEPs), including IFN-γ signature genes, successfully separated responders from non-responders to anti-PD-1 therapy [100]. This evidence concerns the gene IFNG and gastric cancer.